Persistent atrial fibrillation with left atrial low-voltage area: who benefit from additional modification?
NCT03448562 [CPVI Alone Versus CPVI Plus Electrophysiological Substrate Ablation in the LA During SR for the Treatment of Non-PAF (STABLE-SR_II)].
Authors
- Minglong Chen (ORCID: https://orcid.org/0000-0002-9844-486X)
- Nan Wu (ORCID: https://orcid.org/0000-0002-9429-2889)
- Hongwu Chen (ORCID: https://orcid.org/0000-0002-0006-2485)
- Mingfang Li (ORCID: https://orcid.org/0000-0001-8755-6965)
- Hailei Liu (ORCID: https://orcid.org/0009-0002-4867-5341)
- Gang Yang (ORCID: https://orcid.org/0000-0003-1101-7863)
- Youmei Shen (ORCID: https://orcid.org/0000-0002-3449-821X)
- Weizhu Ju (ORCID: https://orcid.org/0000-0002-8327-3308)
- Miaolong Yuan (ORCID: https://orcid.org/0000-0001-8114-8143)
- Kai Gu (ORCID: https://orcid.org/0000-0003-1605-6001)
- Ning Chen (ORCID: https://orcid.org/0009-0007-6650-3689)
- Hengzhi Zhang (ORCID: https://orcid.org/0000-0002-6578-0007)
- Qiuheng Bian (ORCID: https://orcid.org/0009-0008-7302-6072)
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- EP Europace
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1093/europace/euaf095
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China